Longeveron (NASDAQ:LGVN) Shares Up 2.5% – Still a Buy?

Longeveron Inc. (NASDAQ:LGVN)’s stock price shot up 2.5% during trading on Tuesday . The company traded as high as $0.7831 and last traded at $0.7727. 119,736 shares traded hands during mid-day trading, a decline of 70% from the average session volume of 394,153 shares. The stock had previously closed at $0.7540.

Analyst Upgrades and Downgrades

LGVN has been the subject of several research reports. Weiss Ratings lowered Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. Maxim Group lowered Longeveron from a “buy” rating to a “hold” rating in a research note on Monday, May 11th. Wall Street Zen cut Longeveron from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Finally, HC Wainwright cut their price target on Longeveron from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, May 4th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Longeveron has an average rating of “Hold” and an average target price of $5.50.

Longeveron Stock Up 2.5%

The company has a market capitalization of $24.07 million, a PE ratio of -0.68 and a beta of -0.35. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.88 and a current ratio of 3.88. The stock’s 50 day moving average is $0.90 and its 200 day moving average is $0.72.

Longeveron (NASDAQ:LGVN) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.19) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.19). Longeveron had a negative net margin of 1,844.49% and a negative return on equity of 202.41%. The business had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.33 million. On average, sell-side analysts anticipate that Longeveron Inc. will post -0.68 EPS for the current fiscal year.

Hedge Funds Weigh In On Longeveron

An institutional investor recently bought a new position in Longeveron stock. XTX Topco Ltd acquired a new stake in shares of Longeveron Inc. (NASDAQ:LGVN) during the second quarter, according to its most recent filing with the SEC. The fund acquired 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned 0.32% of Longeveron as of its most recent filing with the SEC. Hedge funds and other institutional investors own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.